Clinical Trial Highlights

• TNT Results: Carboplatin Improves Patient Outcomes in Advanced BRCA1/2-Mutated BC
• AC and Weekly Paclitaxel Improve Outcomes in TNBC
• TP53 Mutations Are Associated With Increased Pathologic Complete Response in HER2-Positive BC
• ICE: No Advantage to Adding Capecitabine to Ibandronate in High-Risk Early BC
• Partial and Whole Breast Radiation Have Similar Outcomes in Early BC
• No Survival Benefit When Adding Everolimus to Trastuzumab and Paclitaxel in Advanced HER2-Positive BC
• Results From the EPO-ANE-3010 Study Consistent With US Black Box Labeling